BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat

BioNTech falls as it ends mid-stage trial of mRNA colorectal cancer vaccine

BioNTech stock slides after halting a phase 2 mRNA colorectal cancer trial over survival imbalance. Ripple effect hits Moderna and Merck. Read more here.

BioNTech Stock Dips After BNT122-01 Trial Termination - BioNTech (NASDAQ:BNTX)

BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.

BioNTech Tumbles 8% as Colorectal Cancer Vaccine Trial Fails, Moderna Drops 6%, Pfizer Holds Flat

BioNTech's colorectal cancer vaccine just collapsed in a Phase 2 trial, dragging Moderna down with it despite last week's melanoma triumph, and the fallout is forcing investors to rethink how far mRNA technology can actually reach into solid tumors.

BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine

BioNTech has axed a Phase 2 trial of its personalized mRNA cancer vaccine just a week after Moderna and Merck had breakout success for their own approach in a much different cancer setting. BioNTech said ...

BioNTech Shares Drop 6.6% After Board Terminates Colorectal Cancer Vaccine Study

MAINZ, Germany, August 28, 2026, 10:06 (EDT) - Shares of BioNTech (BNTX.O) fell 6.6% after the board decided to end a trial testing its experimental vaccine for colorectal cancer. Shares of BioNTech ADSs dropped 6.6% to $104.09 at 10:05 EDT. An independent board has advised discontinuing the Phase 2 study for colorectal cancer. Research and…